Hepatitis c Clinical Trial
Official title:
Reaching Out to the UNdiagnosed People Infected With Blood Borne Viral Infections
Title Reaching out to the UNdiagnosed people infected with blood-borne viral infections
(RUNtoBBV) Objectives 1. To study the efficacy of an outreach methodology to increase the
uptake for screening, linkage to care and treatment in (active or former) people who use
drugs (PWUD) Trial design Prospective multicenter interventional cohort design Number of
subjects 336 inclusions (with prevalence of HCV Ab: 30%)
- 168 Antwerp
- 168 Limburg
Selection criteria Inclusion criteria:
- 18 years of age
- History of/ or active drug use
- Written informed consent obtained Exclusion criteria
- Currently enrolled in centralized OST program of Free Clinic or CAD Limburg Endpoints
The following endpoints will be compared between the centers in Limburg and Antwerp:
(Main outcome in bold)
Main objectives:
- Prevalence of blood-borne viral infections in Belgian (former or active) PWUD:
- HCV infection (number of HCV Ab+ / number of screened PWUD)
- HBV infection (number of HBsAg+/number of screened PWUD)
- HIV infection (number of HIV Ab+/number of screened PWUD)
- Analysis of linkage to care to hepatologist/ infectiologist (number of patients who
adhered to their consultation/number of referred patients)
Secondary objectives:
- Analysis of risk behavior/sociodemographics linked to presence of BBV infections
- Analysis of uptake of anti(retro)viral treatment (number of patients started on
treatment/number of patients needing treatment)
- Analysis of treatment adherence (adherence to treatment consultations/total planned
consultations)
- Analysis of treatment outcome (total number of cured or virally suppressed
patients/total number of treated patients)
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
| Recruiting |
NCT04510246 -
Link Hepatitis C Notifications to Treatment in Tasmania
|
N/A | |
| Completed |
NCT03413696 -
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
|
||
| Completed |
NCT03109457 -
Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma
|
||
| Completed |
NCT03118674 -
Harvoni Treatment Porphyria Cutanea Tarda
|
Phase 2 | |
| Completed |
NCT01458054 -
Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults
|
Phase 1 | |
| Completed |
NCT03740230 -
An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs
|
||
| Completed |
NCT03426787 -
Helping Empower Liver and Kidney Patients
|
N/A | |
| Completed |
NCT03627299 -
Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
|
Phase 4 | |
| Completed |
NCT00006301 -
Immune Response to Hepatitis C Virus
|
||
| Active, not recruiting |
NCT03949764 -
The Kentucky Viral Hepatitis Treatment Study
|
Phase 4 | |
| Completed |
NCT03365635 -
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
|
Phase 4 | |
| Recruiting |
NCT04405024 -
Pilot Study on the Feasibility of Systematic Hepatitis C Screening of Hospitalized Patients
|
N/A | |
| Completed |
NCT04525690 -
Improving Inpatient Screening for Hepatitis C
|
N/A | |
| Completed |
NCT04033887 -
Evaluation Study of RDTs Detecting Antibodies Against HCV
|
||
| Withdrawn |
NCT04546802 -
HepATocellular Cancer Hcv Therapy Study
|
Phase 3 | |
| Active, not recruiting |
NCT02961426 -
Strategic Transformation of the Market of HCV Treatments
|
Phase 2/Phase 3 | |
| Completed |
NCT02992184 -
PoC-HCV Genedrive Viral Detection Assay Validation Study
|
N/A | |
| Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
| Completed |
NCT03186313 -
A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection
|
Phase 3 |